Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Sees Large Decrease in Short Interest

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 1,558 shares, a decline of 38.3% from the December 15th total of 2,524 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 3,750 shares, the short-interest ratio is presently 0.4 days. Based on an average daily trading volume, of 3,750 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the shares of the company are sold short.

Fidelity Disruptive Medicine ETF Price Performance

Shares of FMED stock traded down $0.05 during trading hours on Friday, hitting $27.47. The stock had a trading volume of 3,952 shares, compared to its average volume of 9,823. The stock’s 50 day moving average is $27.62 and its 200 day moving average is $25.74. The firm has a market capitalization of $63.18 million, a PE ratio of 41.33 and a beta of 1.00. Fidelity Disruptive Medicine ETF has a twelve month low of $20.69 and a twelve month high of $29.07.

Institutional Investors Weigh In On Fidelity Disruptive Medicine ETF

A hedge fund recently raised its stake in Fidelity Disruptive Medicine ETF stock. Wealth Enhancement Advisory Services LLC increased its stake in shares of Fidelity Disruptive Medicine ETF (NASDAQ:FMED) by 12.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 688,750 shares of the company’s stock after buying an additional 76,538 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 31.31% of Fidelity Disruptive Medicine ETF worth $16,544,000 at the end of the most recent quarter.

Fidelity Disruptive Medicine ETF Company Profile

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.